This study is a prospective, multi-center, proof of principle, phase I human safety study (n=12) evaluating the sequential treatments of the Avance Nerve Graft, a commercially available decellularized processed peripheral nerve allograft, with autologous Bone Marrow Aspirate Concentrate (BMAC), a source of stem cells, for the repair of peripheral nerve injuries of up to 7 cm in length.